These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24007508)

  • 1. Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry.
    Martínez V; Comas J; Arcos E; Díaz JM; Muray S; Cabezuelo J; Ballarín J; Ars E; Torra R
    BMC Nephrol; 2013 Sep; 14():186. PubMed ID: 24007508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry.
    Spithoven EM; Kramer A; Meijer E; Orskov B; Wanner C; Abad JM; Aresté N; de la Torre RA; Caskey F; Couchoud C; Finne P; Heaf J; Hoitsma A; de Meester J; Pascual J; Postorino M; Ravani P; Zurriaga O; Jager KJ; Gansevoort RT; ; ;
    Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4(Suppl 4):iv15-25. PubMed ID: 25165182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure.
    Shaw C; Simms RJ; Pitcher D; Sandford R
    Nephrol Dial Transplant; 2014 Oct; 29(10):1910-8. PubMed ID: 24737444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease.
    Spithoven EM; Kramer A; Meijer E; Orskov B; Wanner C; Caskey F; Collart F; Finne P; Fogarty DG; Groothoff JW; Hoitsma A; Nogier MB; Postorino M; Ravani P; Zurriaga O; Jager KJ; Gansevoort RT; ; ; ; ;
    Kidney Int; 2014 Dec; 86(6):1244-52. PubMed ID: 24827775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark.
    Orskov B; Rømming Sørensen V; Feldt-Rasmussen B; Strandgaard S
    Clin J Am Soc Nephrol; 2010 Nov; 5(11):2034-9. PubMed ID: 20671227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of intracranial hemorrhage associated with autosomal dominant polycystic kidney disease in patients with end stage renal disease.
    Yoo DJ; Agodoa L; Yuan CM; Abbott KC; Nee R
    BMC Nephrol; 2014 Feb; 15():39. PubMed ID: 24571546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease.
    Pirson Y; Christophe JL; Goffin E
    Nephrol Dial Transplant; 1996; 11 Suppl 6():24-8. PubMed ID: 9044324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of autosomal dominant polycystic kidney disease patients on peritoneal dialysis: a national retrospective study based on two French registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network).
    Sigogne M; Kanagaratnam L; Dupont V; Couchoud C; Verger C; Maheut H; Hazzan M; Halimi JM; Barbe C; Canivet E; Petrache A; Dramé M; Rieu P; Touré F
    Nephrol Dial Transplant; 2018 Nov; 33(11):2020-2026. PubMed ID: 29361078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peritoneal dialysis as the first-line renal replacement therapy in patients with autosomal dominant polycystic kidney disease.
    Li L; Szeto CC; Kwan BC; Chow KM; Leung CB; Kam-Tao Li P
    Am J Kidney Dis; 2011 Jun; 57(6):903-7. PubMed ID: 21458901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival after starting renal replacement treatment in patients with autosomal dominant polycystic kidney disease: a single-centre 40-year study.
    Haynes R; Kheradmand F; Winearls CG
    Nephron Clin Pract; 2012; 120(1):c42-7. PubMed ID: 22205054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UK Renal Registry 15th annual report: Chapter 5 survival and causes of death of UK adult patients on renal replacement therapy in 2011: national and centre-specific analyses.
    Steenkamp R; Shaw C; Feest T
    Nephron Clin Pract; 2013; 123 Suppl 1():93-123. PubMed ID: 23774488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.
    Hruskova Z; Pippias M; Stel VS; Abad-Díez JM; Benítez Sánchez M; Caskey FJ; Collart F; De Meester J; Finne P; Heaf JG; Magaz A; Palsson R; Reisæter AV; Salama AD; Segelmark M; Traynor JP; Massy ZA; Jager KJ; Tesar V
    Am J Kidney Dis; 2019 Feb; 73(2):184-193. PubMed ID: 30122544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression.
    Neijenhuis MK; Kievit W; Perrone RD; Sloan JA; Erwin P; Murad MH; Gevers TJG; Hogan MC; Drenth JPH
    BMC Nephrol; 2017 May; 18(1):169. PubMed ID: 28545401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease.
    Simms RJ; Thong KM; Dworschak GC; Ong AC
    Nephrol Dial Transplant; 2016 Jul; 31(7):1130-40. PubMed ID: 26268712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Renal replacement therapy in adult dominant polycystic kidney disease--multicentre study].
    Lezaić V; Ostrić V; Popović G; Vukoje M; Dragolić B; Kostić N; Stojanović M; Labudović M; Mandić M; Djordjević V; Baković J
    Srp Arh Celok Lek; 2008 Dec; 136 Suppl 4():287-93. PubMed ID: 20804097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry.
    Tsakiris D; Simpson HK; Jones EH; Briggs JD; Elinder CG; Mendel S; Piccoli G; dos Santos JP; Tognoni G; Vanrenterghem Y; Valderrabano F
    Nephrol Dial Transplant; 1996; 11 Suppl 7():4-20. PubMed ID: 9067983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is CAPD a viable option among ADPKD with end stage renal disease population in India? Its outcomes and economics.
    Kaul A; Dharshan R; Bhadhuaria D; Prasad N; Gupta A; Sharma RK
    Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):906-11. PubMed ID: 26354561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UK Renal Registry 15th annual report: Chapter 1 UK RRT incidence in 2011: national and centre-specific analyses.
    Gilg J; Rao A; Fogarty D
    Nephron Clin Pract; 2013; 123 Suppl 1():1-28. PubMed ID: 23774484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Spanish Renal Registry: 2013 report and evolution from 2007-2013.
    Martín Escobar E;
    Nefrologia; 2016; 36(2):97-120. PubMed ID: 26895749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease.
    Reed B; Helal I; McFann K; Wang W; Yan XD; Schrier RW
    Nephrol Dial Transplant; 2012 Jul; 27(7):2862-5. PubMed ID: 22207329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.